{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:07:49Z","timestamp":1792591669049,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prolactin deficiency is rare. It generally occurs when pituitary disorders, such as large pituitary tumors, pituitary apoplexy, and other conditions associated with sellar mass effect lead to global failure of pituitary function and hypopituitarism. In these situiations, prolactin is commonly the last pituitary hormone affected, after growth hormone and gonadotropins are lost and thyroid-stimulating hormone and adrenocorticotopic hormone secretion is impaired. Prolactin deficiency accompanies several congenital syndromes due to mutations in\n                    <jats:italic>PROP1<\/jats:italic>\n                    and\n                    <jats:italic>Pit1\/ POU1F<\/jats:italic>\n                    and in X-linked IGSF1 deficiency syndrome, and several aqcuired conditions including Sheehan syndrome, IgG4-related hypophysitis, and immune checkpoint-inhibitor-induced hypophysitis. In women, prolactin deficiency prevents lactation following childbirth among other symptoms associated with hypopituitarism. Human prolactin is not available commercially as replacement therapy. However, recombinant human prolactin administered daily to women with hypoprolactinemia and alactogenesis was found to lead to the production of significant milk volume sufficient for lactation.\n                  <\/jats:p>","DOI":"10.1007\/s11154-024-09902-z","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:02:12Z","timestamp":1727841732000},"page":"1041-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prolactin deficiency in the context of other pituitary hormone abnormalities"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3894","authenticated-orcid":false,"given":"Ilan","family":"Shimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"9902_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","volume":"19","author":"C Bole-Feysot","year":"1998","unstructured":"Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19:225\u201368. https:\/\/doi.org\/10.1210\/edrv.19.3.0334.","journal-title":"Endocr Rev"},{"key":"9902_CR2","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523\u201331. https:\/\/doi.org\/10.1152\/physrev.2000.80.4.1523.","journal-title":"Physiol Rev"},{"key":"9902_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ror.0.0010001","volume":"1","author":"CJ Watson","year":"1996","unstructured":"Watson CJ, Burdon TG. Prolactin signal transduction mechanisms in the mammary gland: the role of the Jak\/Stat pathway. Rev Reprod. 1996;1:1\u20135. https:\/\/doi.org\/10.1530\/ror.0.0010001.","journal-title":"Rev Reprod"},{"key":"9902_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0015-0282(16)59769-6","volume":"49","author":"A Kauppila","year":"1988","unstructured":"Kauppila A, Martikainen H, Puistola U, Reinil\u00e4 M, R\u00f6nnberg L. Hypoprolactinemia and ovarian function. Fertil Steril. 1988;49:437\u201341. https:\/\/doi.org\/10.1016\/s0015-0282(16)59769-6.","journal-title":"Fertil Steril"},{"key":"9902_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11154-015-9322-3","volume":"16","author":"G Rastrelli","year":"2015","unstructured":"Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16:233\u201348. https:\/\/doi.org\/10.1007\/s11154-015-9322-3.","journal-title":"Rev Endocr Metab Disord"},{"key":"9902_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"Corona G, Mannucci E, Jannini EA, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009;6:1457\u201366. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x.","journal-title":"J Sex Med"},{"key":"9902_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1210\/mend.6.7.1508218","volume":"6","author":"I Pellegrini","year":"1992","unstructured":"Pellegrini I, Lebrun J, Ali S, Kelly P. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 1992;6:1023\u201331. https:\/\/doi.org\/10.1210\/mend.6.7.1508218.","journal-title":"Mol Endocrinol"},{"key":"9902_CR8","first-page":"91","volume-title":"Diagnosis and management of pituitary tumors","author":"BW Scheithauer","year":"2001","unstructured":"Scheithauer BW, Horvath E, Lloyd RV, Kovacs K. Pathology of pituitary adenoma and pituitary hyperplasia. In: Thapar K, Kovacs K, Scheithauer BW, Lloyd RV, editors. Diagnosis and management of pituitary tumors. Totowa, NJ: Humana; 2001. pp. 91\u2013154."},{"key":"9902_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ng0298-147","volume":"18","author":"W Wu","year":"1998","unstructured":"Wu W, Cogan JD, Pfaffle RW, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet. 1998;18:147\u20139. https:\/\/doi.org\/10.1038\/ng0298-147.","journal-title":"Nat Genet"},{"issue":"Suppl 5","key":"9902_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000110610","volume":"68","author":"D Kelberman","year":"2007","unstructured":"Kelberman D, Dattani MT. Hypopituitarism oddities: congenital causes. Horm Res. 2007;68(Suppl 5):138\u201344. https:\/\/doi.org\/10.1159\/000110610.","journal-title":"Horm Res"},{"key":"9902_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ng0492-56","volume":"1","author":"K Tatsumi","year":"1992","unstructured":"Tatsumi K, Miyai K, Notomi T, et al. Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nat Genet. 1992;1:56\u20138. https:\/\/doi.org\/10.1038\/ng0492-56.","journal-title":"Nat Genet"},{"key":"9902_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.mce.2006.12.019","volume":"265\u2013266","author":"RD Mullen","year":"2007","unstructured":"Mullen RD, Colvin SC, Hunter CS, et al. Roles of the LHX3 and LHX4 LIM-homeodomain factors in pituitary development. Mol Cell Endocrinol. 2007;265\u2013266:190\u20135. https:\/\/doi.org\/10.1016\/j.mce.2006.12.019.","journal-title":"Mol Cell Endocrinol"},{"key":"9902_CR13","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1210\/jc.2007-2389","volume":"93","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Saveanu A, Reynaud R, et al. A novel dysfunctional LHX4 mutation with high phenotypical variability in patients with hypopituitarism. J Clin Endocrinol Metab. 2008;93:2790\u20139. https:\/\/doi.org\/10.1210\/jc.2007-2389.","journal-title":"J Clin Endocrinol Metab"},{"key":"9902_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1210\/jc.2015-3880","volume":"101","author":"SD Joustra","year":"2016","unstructured":"Joustra SD, Heinen CA, Schoenmakers N, et al. IGSF1 clinical care group. IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. J Clin Endocrinol Metab. 2016;101:1627\u201336. https:\/\/doi.org\/10.1210\/jc.2015-3880.","journal-title":"J Clin Endocrinol Metab"},{"key":"9902_CR15","doi-asserted-by":"publisher","first-page":"e3021","DOI":"10.1210\/clinem\/dgab201","volume":"106","author":"M Moriwaki","year":"2021","unstructured":"Moriwaki M, Welt CK. PRL mutation causing alactogenesis: insights into prolactin structure and function relationships. J Clin Endocrinol Metab. 2021;106:e3021\u20136. https:\/\/doi.org\/10.1210\/clinem\/dgab201.","journal-title":"J Clin Endocrinol Metab"},{"key":"9902_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/b:pitu.0000023425.20854.8e","volume":"6","author":"F Kelestimur","year":"2003","unstructured":"Kelestimur F. Sheehan\u2019s syndrome. Pituitary. 2003;6:181\u20138. https:\/\/doi.org\/10.1023\/b:pitu.0000023425.20854.8e.","journal-title":"Pituitary"},{"key":"9902_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-10-1004","volume":"164","author":"HL Kristjansdottir","year":"2011","unstructured":"Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA. Sheehan\u2019s syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol. 2011;164:349\u201354. https:\/\/doi.org\/10.1530\/EJE-10-1004.","journal-title":"Eur J Endocrinol"},{"key":"9902_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2265.1980.tb02714","volume":"12","author":"M Shahmanesh","year":"1980","unstructured":"Shahmanesh M, Ali Z, Pourmand M, Nourmand I. Pituitary function tests in Sheehan\u2019s syndrome. Clin Endocrinol (Oxf). 1980;12:303\u201311. https:\/\/doi.org\/10.1111\/j.1365-2265.1980.tb02714.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9902_CR19","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00701-022-05231-9","volume":"164","author":"R Bhargava","year":"2022","unstructured":"Bhargava R, Hussein Z, Dorward NL, et al. IgG4-related hypophysitis: a retrospective cohort study. Acta Neurochir (Wien). 2022;164:2095\u2013103. https:\/\/doi.org\/10.1007\/s00701-022-05231-9.","journal-title":"Acta Neurochir (Wien)"},{"key":"9902_CR20","doi-asserted-by":"publisher","first-page":"5382640","DOI":"10.1155\/2019\/5382640","volume":"182019","author":"Y Li","year":"2019","unstructured":"Li Y, Gao H, Li Z, Zhang X, Ding Y, Li F. Clinical characteristics of 76 patients with IgG4-related hypophysitis: a systematic literature review. Int J Endocrinol. 2019;182019:5382640. https:\/\/doi.org\/10.1155\/2019\/5382640.","journal-title":"Int J Endocrinol"},{"key":"9902_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/imr.13247","volume":"318","author":"N Singh","year":"2023","unstructured":"Singh N, Hocking AM, Buckner JH. Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity. Immunol Rev. 2023;318:81\u20138. https:\/\/doi.org\/10.1111\/imr.13247.","journal-title":"Immunol Rev"},{"key":"9902_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","volume":"58","author":"L Brilli","year":"2017","unstructured":"Brilli L, Danielli R, Ciuoli C, et al. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine. 2017;58:535\u201341. https:\/\/doi.org\/10.1007\/s12020-017-1289-2.","journal-title":"Endocrine"},{"key":"9902_CR23","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1530\/EJE-19-016","volume":"181","author":"F Albarel","year":"2019","unstructured":"Albarel F, Castinetti F, Brue T. Management of endocrine disease: immune check point inhibitors-induced hypophysitis. Eur J Endocrinol. 2019;181:R107\u201318. https:\/\/doi.org\/10.1530\/EJE-19-016.","journal-title":"Eur J Endocrinol"},{"key":"9902_CR24","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1210\/jc.2013-2411","volume":"98","author":"S Iwama","year":"2013","unstructured":"Iwama S, Welt CK, Romero CJ, Radovick S, Caturegli P. Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells. J Clin Endocrinol Metab. 2013;98:3920\u20135. https:\/\/doi.org\/10.1210\/jc.2013-2411.","journal-title":"J Clin Endocrinol Metab"},{"key":"9902_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/BF03346292","volume":"30","author":"Y Toledano","year":"2007","unstructured":"Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30:268\u201373. https:\/\/doi.org\/10.1007\/BF03346292.","journal-title":"J Endocrinol Invest"},{"key":"9902_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1530\/eje.1.01895","volume":"152","author":"M Bondanelli","year":"2005","unstructured":"Bondanelli M, Ambrosio MR, Zatelli MC, De Marinis L, degli Uberti EC. Hypopituitarism after traumatic brain injury. Eur J Endocrinol. 2005;152:679\u201391. https:\/\/doi.org\/10.1530\/eje.1.01895.","journal-title":"Eur J Endocrinol"},{"key":"9902_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1365-2265.2003.01916.x","volume":"59","author":"A Mukherjee","year":"2003","unstructured":"Mukherjee A, Murray RD, Columb B, Gleeson HK, Shalet SM. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis. Clin Endocrinol (Oxf). 2003;59:743\u20138. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01916.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9902_CR28","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1210\/jc.2005-2491","volume":"91","author":"A Mukherjee","year":"2006","unstructured":"Mukherjee A, Ryder WD, J\u00f6stel A, Shalet SM. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-deficient adults. J Clin Endocrinol Metab. 2006;91:2520\u20135. https:\/\/doi.org\/10.1210\/jc.2005-2491.","journal-title":"J Clin Endocrinol Metab"},{"key":"9902_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1746-4358-2-10","volume":"2","author":"G Page-Wilson","year":"2007","unstructured":"Page-Wilson G, Smith PC, Welt CK. Short-term prolactin administration causes expressible galactorrhea but does not affect bone turnover: pilot data for a new lactation agent. Int Breastfeed J. 2007;2:10. 10.1186\/1.","journal-title":"Int Breastfeed J"},{"key":"9902_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2265.2010.03850.x","volume":"73","author":"CE Powe","year":"2010","unstructured":"Powe CE, Allen M, Puopolo KM, et al. Recombinant human prolactin for the treatment of lactation insufficiency. Clin Endocrinol (Oxf). 2010;73:645\u201353. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03850.x.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09902-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-024-09902-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-024-09902-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T10:06:44Z","timestamp":1733566004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-024-09902-z"}},"subtitle":["Special issue: hypoprolactinemia: a neglected endocrine disorder"],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9902"],"URL":"https:\/\/doi.org\/10.1007\/s11154-024-09902-z","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"25 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}